Lausanne, Switzerland (ots/PRNewswire) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical ...
Lausanne (ots) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm ...
Lausanne, Switzerland (ots) - - International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics - The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - During the coronavirus pandemic, the Swiss National Science Foundation (SNSF) supported a total of 114 Covid-19 research projects, for which it used funding of over CHF 45 million. In the National Research Programme "Covid-19" (NRP 78), around 200 researchers are working in 28 projects with a total budget of CHF 20 million. Another research programme on Covid-19 is about to start. It was the first time the ...
Geneva (ots/PRNewswire) - Recognized as D&I leader by the Cercle Suisse des Administratrices Firmenich, the world's largest privately-owned fragrance and taste company, has announced it has been recognized for its exemplary leadership in Diversity & Inclusion, winning the Cercle Suisse des Administratrices Grandes Entreprises Award 2022. The Cercle Suisse des Administratrices is an association that promotes diversity and ...
Geneva (ots/PRNewswire) - Firmenich, the world's largest privately-owned fragrance and taste company, is proud to announce the appointment of Dr Eric Frérot as Distinguished Scientist. This nomination acknowledges his successful track-record within R&D, his instrumental role in breakthrough innovations, and his consistent exceptional performance in the field of science. He is one of only seven scientists inside the ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Pubescent oak trees thrive even at higher temperatures, in part because they are active earlier in the year. Researchers supported by the SNSF put the trees of the future to the test. As trees grow, they absorb ever greater amounts of CO2 from the atmosphere. Consequently, the health of trees both determines climate and is determined by it. During ...
Compass Financial Technologies
Lausanne, Switzerland and London (ots/PRNewswire) - Compass Financial Technologies, a Swiss and French based EU regulated index provider and Marex Solutions, Marex's hedging and investment solutions arm that specialises in customised derivative products, collaborate to offer digital asset investment solutions for institutional investors. Marex will leverage the ...
Berlin/Lausanne/Barcelona/Munich (ots) - New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika - an app-based DTx platform empowering people affected by cancer. Berlin-based digital health company Fosanis, the ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Last year, the SNSF selected around 1800 research projects for funding. It also launched new funding measures because Swiss researchers are not able to participate in important areas of the Horizon Europe programme. Expanding knowledge and solving problems. That is what thousands of SNSF-funded research teams do at Swiss universities and other higher education institutions. Their curiosity and their ...
Compass Financial Technologies
Lausanne, Switzerland (ots/PRNewswire) - Compass Financial Technologies, a leading crypto index provider that calculates indices that track over $5bn in assets announces the launch of the Compass Crypto Basket Fundamental DeFi Index (CCBFDEFI) - providing a reliable institutional benchmark to one of the fastest growing sectors in the crypto industry. The CCBFDEFI is ...
Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...
Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...
elea Foundation for Ethics in Globalization
Geneva (ots/PRNewswire) - Firmenich, the world's largest privately-owned fragrance and taste company, has won Digital Innovation Of The Year at the Digital Economy Award 2021 in Switzerland. This recognition celebrates the Group's ground-breaking Artificial Intelligence (AI) capabilities and its new Formulae ...
Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today having invested $4M inMekonos, a biotech company building the future of cell ...
Poda Lifestyle and Wellness Ltd.
Vancouver, Bc (ots/PRNewswire) - PODA HOLDINGS, INC. ("Poda" or the "Company") (CSE: PODA) (FSE: 99L) (OTC: PODAF)is pleased to announce that former big tobacco sales leader, Christoph Tepr ("Tepr"), has joined Poda. Tepr has accepted an upcoming employment position with the Company as Vice President of European Sales & International Expansion, which is expected to commence on January 17th, 2022. In the interim, Tepr has ...
Lausanne, Switzerland / Boston, USA (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical ...
Lausanne, Switzerland – Tangerang, Indonesia (ots) - Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, ...
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research –Dr. Shumpei Ishikawa and ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - A very aggressive type of cancer has provided a team of researchers supported by the Swiss National Science Foundation with an answer to the question of which tumour cells are at risk of spreading. Cancer treatment is sometimes complicated by the heterogeneity of the cells that form the tumour mass. The problem is how to identify the few cells that are capable of triggering metastases. Thanks to work carried ...
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...